Skip to main content

Table 2 Overview of eligible medication classes included

From: Evidence for pharmacological interventions to reduce cardiovascular risk for patients with chronic kidney disease: a study protocol of an evidence map

Antihypertensives

Lipid-lowering medications

Anti-platelets and anticoagulants

Glucose-lowering medications

1. Alpha-blockers

1. HMG-CoA inhibitors

1. Salycates

1. Biguanides

2. ACE-inhibitors

2. Fibrates

2. P2Y12 inhibitors

2. Sulfonylureas

3. Angiotensin receptor blockers

3. PCSK-9 inhibitors

3. GP IIb/IIIa inhibitors

3. DPP-4 inhibitors

4. Aldosterone antagonist

4. Niacin/nicotinic acid

4. Other platelet inhibitors

4. GLP-1 receptor agonists

5. Renin inhibitors

5. Bile acid sequestrants

5. Heparins

5. SGLT-2 inhibitors

6. Beta-blockers

6. Selective cholesterol absorption inhibitors

6. Vitamin K antagonists

6. Alpha-glucosidase inhibitors

7. Dihydropyridine calcium channel blockers

7. Other lipid-lowering agents

7. Direct oral anti-coagulants

7. Thiazolidinediones

8. Non-dihydropyridine calcium channel blockers

  

8. Meglitinides

9. Thiazide(-like) diuretics

  

9. Insulin

10. Loop diuretics

   

11. Vasodilators

   

12. Centrally acting antihypertensives

   
  1. Other lipid-lowering medications: probucol, policosanol, mipomersen, lomitapide, bempedoic acid, and icosapent ethyl
  2. Other antiplatelet medications: dipyridamole, picotamide, ticlopidine, indobufen, iloprost, triflusal, cilostazol, and vorapaxar
  3. Abbreviations: ACE angiotensin-converting enzyme, HMG-CoA β-hydroxy β-methylglutaryl co-enzyme A, PCSK-9 proprotein convertase subtilisin/kexin type 9, GP IIb/IIIa glycoprotein IIb/IIIa, DPP-4 dipeptidyl-peptidase 4, GLP-1 glucagonlike peptide-1, SGLT-2 sodium-glucose cotransporter-2
Back to article page

Systematic Reviews

ISSN: 2046-4053